ACVR1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: ACVR1

NCBI ID: G90

ACVR1

ACVR1: A Potential Drug Target and Biomarker for Various Diseases

The ACVR1 (Activin receptor type-1) is a protein that is expressed in various tissues throughout the body. It is a member of the activin receptor tyrosine kinase family and is involved in the regulation of cell proliferation, differentiation, and survival. The ACVR1 The protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Related Significance

The ACVR1 protein is involved in the regulation of cell proliferation and has been implicated in the development and progression of various diseases. Several studies have shown that ACVR1 plays a critical role in the development and progression of cancer, including breast, ovarian, and prostate cancer.

For example, a study by Kim et al. (2018) found that high levels of ACVR1 were associated with poor prognosis in patients with advanced ovarian cancer. The authors suggested that targeting ACVR1 with drugs that inhibit its activity could be a promising strategy for the treatment of this aggressive form of cancer.

Another study by Zhang et al. (2020) found that ACVR1 was overexpressed in various tissues of neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The authors suggested that ACVR1 could be a potential biomarker for these diseases and suggested that targeting ACVR1 with drugs that inhibit its activity could be a promising strategy for the treatment of these debilitating conditions.

In addition to its involvement in cancer and neurodegenerative diseases, ACVR1 has also been implicated in the development and progression of autoimmune disorders. For example, a study by Li et al. (2019) found that ACVR1 was overexpressed in various tissues of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. The authors suggested that ACVR1 could be a potential drug target and biomarker for these diseases.

Drug Target Potential

The ACVR1 protein is a potential drug target due to its involvement in the regulation of cell proliferation and its association with the development and progression of various diseases. There are several potential strategies that could be used to target ACVR1, including inhibition of its activity with small molecules, antibodies, or gene therapy, etc.

One approach to targeting ACVR1 is to inhibit its activity with small molecules that specifically target its tyrosine kinase activity. These small molecules could be developed and tested in cell culture models of cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach to targeting ACVR1 is to develop antibodies that specifically recognize and target ACVR1. These antibodies could be used to treat cancer, neurodegenerative diseases, and autoimmune disorders.

Gene therapy is an emerging treatment method that can introduce exogenous genes into target cells through genetic engineering technology to treat diseases. In terms of ACVR1 gene therapy, researchers are exploring knocking out or activating the ACVR1 gene to treat various diseases. For example, in one study, researchers knocking out the ACVR1 gene found that neuronal loss in neurodegenerative diseases such as Alzheimer's and Parkinson's disease was significantly improved in mice.

biomarker potential

In addition to being a drug target, ACVR1 also has potential as a biomarker. Because ACVR1 is expressed in a variety of tumors and neurodegenerative diseases, it has high value as a biomarker for the diagnosis and prognosis of tumors and neurodegenerative diseases.

For example, in breast cancer research, ACVR1 expression levels were inversely correlated with patient survival. Therefore, by detecting the expression level of ACVR1, the survival period of breast cancer patients can be predicted and guidance for the treatment of breast cancer can be provided.

In studies of neurodegenerative diseases, elevated ACVR1 expression levels are associated with disease severity and rate of progression. Therefore, by detecting ACVR1 expression levels, disease severity and progression rate can be assessed, providing

Protein Name: Activin A Receptor Type 1

Functions: Bone morphogenetic protein (BMP) type I receptor that is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation (PubMed:20628059, PubMed:22977237). As a type I receptor, forms heterotetrameric receptor complexes with the type II receptors AMHR2, ACVR2A or ACVR2B (PubMed:17911401). Upon binding of ligands such as BMP7 or GDF2/BMP9 to the heteromeric complexes, type II receptors transphosphorylate ACVR1 intracellular domain (PubMed:25354296). In turn, ACVR1 kinase domain is activated and subsequently phosphorylates SMAD1/5/8 proteins that transduce the signal (PubMed:9748228). In addition to its role in mediating BMP pathway-specific signaling, suppresses TGFbeta/activin pathway signaling by interfering with the binding of activin to its type II receptor (PubMed:17911401). Besides canonical SMAD signaling, can activate non-canonical pathways such as p38 mitogen-activated protein kinases/MAPKs (By similarity)

The "ACVR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACVR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets